Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93. Following the completion of the transaction, the director directly owned 92,211 shares in the company, valued at $2,418,694.53. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total value of $301,058.00.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The shares were sold at an average price of $26.07, for a total value of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 3.0%

IMNM stock opened at $27.20 on Friday. The firm’s 50-day moving average price is $22.20 and its two-hundred day moving average price is $22.24. Immunome, Inc. has a 12-month low of $8.66 and a 12-month high of $28.62. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -10.75 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Equities analysts predict that Immunome, Inc. will post -2.3 EPS for the current year.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IMNM. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday. Leerink Partners cut their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and an average target price of $34.64.

Institutional Trading of Immunome

Several large investors have recently bought and sold shares of IMNM. Renaissance Technologies LLC purchased a new position in shares of Immunome in the 1st quarter worth about $1,507,000. California State Teachers Retirement System grew its position in Immunome by 66.3% during the 1st quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock valued at $2,437,000 after purchasing an additional 44,432 shares during the last quarter. Nan Fung Trinity HK Ltd. grew its position in Immunome by 20.7% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after purchasing an additional 122,450 shares during the last quarter. Vanguard Group Inc. increased its stake in Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Finally, Profund Advisors LLC increased its stake in Immunome by 121.7% during the 4th quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after purchasing an additional 23,440 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.